Outlining novel cellular adjuvant products for therapeutic vaccines against cancer (Q33997622)

30 July 2017

1 reference

title

Outlining novel cellular adjuvant products for therapeutic vaccines against cancer (English)

1 reference

30 July 2017

1 reference

Josianne Nitcheu Tefit

series ordinal

1

1 reference

PubMed ID

21854313

30 July 2017

Vincent Serra

series ordinal

2

1 reference

30 July 2017

1 August 2011

1 reference

Expert Review of Vaccines

30 July 2017

1 reference

30 July 2017

10

1 reference

30 July 2017

8

1 reference

30 July 2017

1207-1220

1 reference

Cancer immunotherapy: moving beyond current vaccines

30 July 2017

1 reference

Immunological concepts of vaccine adjuvant activity

21 January 2018

1 reference

The path to a successful vaccine adjuvant--'the long and winding road'.

21 January 2018

1 reference

Vaccine adjuvants: putting innate immunity to work

21 January 2018

1 reference

Mechanism of action of licensed vaccine adjuvants

21 January 2018

1 reference

Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling

21 January 2018

1 reference

AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity

21 January 2018

1 reference

MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates

21 January 2018

1 reference

Adjuvants: current status, clinical perspectives and future prospects

21 January 2018

1 reference

Innate immunity: impact on the adaptive immune response

21 January 2018

1 reference

Triggering TLR signaling in vaccination

21 January 2018

1 reference

Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration

21 January 2018

1 reference

Indoleamine 2,3-dioxygenase: is it an immune suppressor?

21 January 2018

1 reference

History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story

21 January 2018

1 reference

Pathogen recognition in the innate immune response.

21 January 2018

1 reference

Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials

21 January 2018

1 reference

Immunotherapy of malignant melanoma

21 January 2018

1 reference

Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial

21 January 2018

1 reference

Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits

21 January 2018

1 reference

Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise

21 January 2018

1 reference

Optimal sample size for a series of pilot trials of new agents

21 January 2018

1 reference

Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides.

21 January 2018

1 reference

Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix

21 January 2018

1 reference

GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development

21 January 2018

1 reference

Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion

21 January 2018

1 reference

Immunotherapy as part of combinations for the treatment of cancer

21 January 2018

1 reference

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group

21 January 2018

1 reference

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.

21 January 2018

1 reference

Melacine: an allogeneic melanoma tumor cell lysate vaccine

21 January 2018

1 reference

Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma

21 January 2018

1 reference

Vaccination with Theratope (STn-KLH) as treatment for breast cancer

21 January 2018

1 reference

Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses

21 January 2018

1 reference

Toll-like receptor 3 promotes cross-priming to virus-infected cells.

21 January 2018

1 reference

Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R).

21 January 2018

1 reference

Crystal structure of human toll-like receptor 3 (TLR3) ectodomain

21 January 2018

1 reference

Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus

21 January 2018

1 reference

Innate immune recognition of viral infection

21 January 2018

1 reference

Toll-like receptors and Type I interferons

21 January 2018

1 reference

The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses

21 January 2018

1 reference

Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models

21 January 2018

1 reference

Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod

21 January 2018

1 reference

Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7

21 January 2018

1 reference

Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults

21 January 2018

1 reference

A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations

21 January 2018

1 reference

Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells

21 January 2018

1 reference

Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA.

21 January 2018

1 reference

First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer.

21 January 2018

1 reference

An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma

21 January 2018

1 reference

Toll-like receptors: critical proteins linking innate and acquired immunity

21 January 2018

1 reference

Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization

21 January 2018

1 reference

Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides

21 January 2018

1 reference

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.

21 January 2018

1 reference

Advances in saponin-based adjuvants

21 January 2018

1 reference

21 January 2018

ISCOMs and ISCOMATRIX.

1 reference

21 January 2018

1 reference

Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21.

21 January 2018

1 reference

Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant

21 January 2018

1 reference

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

21 January 2018

1 reference

Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma

21 January 2018

1 reference

Adjuvant activity of incomplete Freund's adjuvant

21 January 2018

1 reference

Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants

21 January 2018

1 reference

Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines

21 January 2018

1 reference

Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant

21 January 2018

1 reference

Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations

21 January 2018

1 reference

Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720.

21 January 2018

1 reference

Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression

21 January 2018

1 reference

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

21 January 2018

1 reference

Emulsion-based adjuvants for influenza vaccines.

21 January 2018

1 reference

Immunostimulatory colloidal delivery systems for cancer vaccines.

21 January 2018

1 reference

Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses.

21 January 2018

1 reference

Use of cellular and cytokine adjuvants in the immunotherapy of cancer

21 January 2018

1 reference

Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells

21 January 2018

1 reference

Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma

21 January 2018

1 reference

Interleukin-12 in anti-tumor immunity and immunotherapy.

21 January 2018

1 reference

Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer.

21 January 2018

1 reference

21 January 2018

The biology of NKT cells

1 reference

Lysosomal glycosphingolipid recognition by NKT cells

21 January 2018

1 reference

Recognition of bacterial glycosphingolipids by natural killer T cells

21 January 2018

1 reference

Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections.

21 January 2018

1 reference

Regulation of immune responses by CD1d-restricted natural killer T cells

21 January 2018

1 reference

Adjuvant activity mediated by iNKT cells

21 January 2018

1 reference

Application of natural killer T cells in antitumor immunotherapy

21 January 2018

1 reference

Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection.

21 January 2018

1 reference

Glycolipid antigen induces long-term natural killer T cell anergy in mice

21 January 2018

1 reference

Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients

21 January 2018

1 reference

Overview of vaccinology with special reference to papillomavirus vaccines

21 January 2018

1 reference

Designer adjuvants for enhancing the efficacy of infectious disease and cancer vaccines based on suppression of regulatory T cell induction

21 January 2018

1 reference

Gene therapy for antitumor vaccination

21 January 2018

1 reference

Therapeutic HPV DNA vaccines

21 January 2018

1 reference

In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production

21 January 2018

1 reference

Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERV.11.84

1 reference

30 July 2017

1 reference

PubMed ID

21854313